Daewoong Pharmaceutical announced that it will participate in "CPhI Worldwide 2022", the world's largest pharmaceutical bioconference held at the Frankfurt International Exhibition Center, Germany for 3 days from November 1.
This year, CPhI Worldwide will be attended by more than 2,500 companies and 45,000 industry representatives from 165 countries.
Daewoong Pharmaceutical has set up its own booth and will target existing and potential business partners with corporate brands and in-house R&D new drugs such as gastroesophageal reflux disease treatment "FexuClue", diabetes drug "Enavogliflozin", pulmonary fibrosis treatment "DWN12088", improved new drugs, and generics.
The company is scheduled to meet with more than 100 companies in the US, Europe, China, Latin America, India, the Middle East and CIS regions. At the meeting, various license-in/out, joint development, and CDMO projects will be discussed.
Through this conference, Daewoong Pharmaceutical plans to advance negotiations for FexuClue with candidate partners in unexploited regions such as the US, Latin America, India, and CIS.
The company is also expected that it will be able to discover a large number of new partners for Enavogliflozin, which is expected to receive domestic approval within this year.
Daewoong Pharm expects that Nabota, which has established itself as a global brand, will receive great attention.
In addition, new partnerships are being pursued for export of DWN12088, ulcerative colitis treatment "BBT-401", and anticancer treatment "LUPRON DEPOT" sustained-release injection.
Daewoong Pharmaceutical CEO Jeon Seng-ho said, “Through this participation, Daewoong Pharmaceutical will promote its excellent R&D capabilities and new drug pipeline, and spur overseas market penetration.”
Meanwhile, FexuClue has already signed a 1.2 trillion won technology export contract with 15 countries including China, the US and Brazil before its official launch in Korea in July. It has now applied for permits in eight countries around the world.
